Lyra Therapeutics (LYRA) Current Deferred Revenue (2021 - 2025)
Historic Current Deferred Revenue for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to $11.9 million.
- Lyra Therapeutics' Current Deferred Revenue fell 481.19% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year decrease of 481.19%. This contributed to the annual value of $12.3 million for FY2024, which is 1112.08% down from last year.
- Lyra Therapeutics' Current Deferred Revenue amounted to $11.9 million in Q3 2025, which was down 481.19% from $11.9 million recorded in Q2 2025.
- In the past 5 years, Lyra Therapeutics' Current Deferred Revenue registered a high of $16.2 million during Q1 2022, and its lowest value of $9.8 million during Q3 2021.
- Over the past 5 years, Lyra Therapeutics' median Current Deferred Revenue value was $13.0 million (recorded in 2024), while the average stood at $13.3 million.
- Per our database at Business Quant, Lyra Therapeutics' Current Deferred Revenue soared by 5611.22% in 2022 and then plummeted by 1256.56% in 2024.
- Quarter analysis of 5 years shows Lyra Therapeutics' Current Deferred Revenue stood at $11.7 million in 2021, then skyrocketed by 31.05% to $15.4 million in 2022, then decreased by 10.15% to $13.8 million in 2023, then decreased by 11.12% to $12.3 million in 2024, then decreased by 3.19% to $11.9 million in 2025.
- Its Current Deferred Revenue was $11.9 million in Q3 2025, compared to $11.9 million in Q2 2025 and $12.1 million in Q1 2025.